GlobeNewswire: VisionGate, Inc. Contains the last 10 of 12 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:18:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/22/1905359/0/en/VisionGate-Announces-an-Exclusive-Global-License-Manufacturing-and-Supply-Agreement-for-Iloprost-VisionGate-s-Phase-2-Oral-Lung-Cancer-Interception-Drug.html?f=22&fvtc=4&fvtv=39817VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug2019-08-22T12:00:00Z<![CDATA[VisionGate remains on track for an FDA meeting to finalize the clinical study and approval path for Iloprost, the first oral lung cancer interception drug VisionGate remains on track for an FDA meeting to finalize the clinical study and approval path for Iloprost, the first oral lung cancer interception drug]]>https://www.globenewswire.com/news-release/2019/01/29/1707066/0/en/VisionGate-Announces-Lung-Cancer-Prevention-Trial-Progress.html?f=22&fvtc=4&fvtv=39817VisionGate Announces Lung Cancer Prevention Trial Progress2019-01-29T16:32:00Z<![CDATA[Selects PCI Pharma Services as Manufacturing Partner for Oral Iloprost and Receives Initial API Shipment Selects PCI Pharma Services as Manufacturing Partner for Oral Iloprost and Receives Initial API Shipment]]>https://www.globenewswire.com/news-release/2018/10/11/1620095/0/en/VisionGate-Inc-Appoints-R-John-Glasspool-as-Chief-Operating-and-Strategy-Officer-and-member-of-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=39817VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors2018-10-11T14:06:34Z<![CDATA[Seattle, WA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., an integrated, clinical-stage, oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of R. John Glasspool as its Chief Operating and Strategy Officer.]]>https://www.globenewswire.com/news-release/2018/09/24/1574752/0/en/VisionGate-s-Cell-CT-Platform-Uses-3D-Cell-Morphometry-and-Artificial-Intelligence-to-Detect-an-Immunotherapy-Predictive-Biomarker-and-Cancer-Associated-Cells-that-have-undergone-M.html?f=22&fvtc=4&fvtv=39817VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy2018-09-24T10:00:00Z<![CDATA[Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer]]>https://www.globenewswire.com/news-release/2018/06/14/1524874/0/en/VisionGate-Announces-New-Appointment-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=39817VisionGate Announces New Appointment to the Board of Directors2018-06-14T18:06:17Z<![CDATA[Experienced Pharma, Diagnostics and Biotech Executive Strengthens Company Leadership Experienced Pharma, Diagnostics and Biotech Executive Strengthens Company Leadership]]>https://www.globenewswire.com/news-release/2018/04/17/1480585/0/en/VisionGate-Inc-Appoints-Randal-Buness-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=39817VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer2018-04-17T22:34:38Z<![CDATA[SEATTLE, WA, April 17, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of Randal Buness, CPA, MBA as Chief Financial Officer. Mr. Buness is a senior financial executive with over 25 years of results-oriented leadership. Prior to joining VisionGate, he served as Chief Financial Officer of multiple high-growth, public and private medical and high technology companies. Most recently he served as CFO of Cayenne Medical, Inc., a medical device company that was acquired by Zimmer Biomet. His financial background includes expertise in venture capital, public stock offerings, and mergers and acquisitions. Early in his career, Mr. Buness spent ten years in public accounting at Ernst & Young and PricewaterhouseCoopers.“Randy Buness brings exceptional public company and IPO process experience to VisionGate, and we are very pleased to have a seasoned strategic financial professional join our Executive Team”, said Alan C. Nelson, PhD, Chairman and CEO. ” This key appointment comes at an important time as VisionGate business is accelerating and as we continue to invest and grow toward a commercial stage company”, Dr. Nelson added.For more information on VisionGate, please visit http://www.visiongate3d.com.]]>https://www.globenewswire.com/news-release/2018/04/16/1472110/0/en/VisionGate-s-Cell-CT-3D-Cellular-Imaging-Platform-Detects-the-Presence-of-Cancer-Associated-Cells-CACs-that-have-undergone-Malignancy-Associated-Change-MAC.html?f=22&fvtc=4&fvtv=39817VisionGate’s Cell-CT™ 3D Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC)2018-04-16T13:23:47Z<![CDATA[Important New Research Presented at the 2018 AACR Annual Meeting Important New Research Presented at the 2018 AACR Annual Meeting]]>https://www.globenewswire.com/news-release/2018/04/12/1469527/0/en/VisionGate-Lung-Cancer-3D-Cellular-Imaging-Research-to-be-Featured-as-a-Late-Breaking-Abstract-at-the-AACR-Annual-Meeting-2018.html?f=22&fvtc=4&fvtv=39817VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 20182018-04-12T17:46:26Z<![CDATA[SEATTLE, WA, April 12, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. The abstract presentation includes a breakthrough research study using the Company’s Cell-CT™ platform 3D cellular imaging technology to detect subtle alterations in cellular and nuclear architecture in non-cancerous cells caused by the “field effect” that cancer cells exert on their microenvironment – known as Malignancy Associated Change (MAC). “We are excited to present this important study at this year’s AACR Annual Meeting,” said Michael Meyer, VisionGate’s Chief Technology Officer, “The acceptance of this abstract and its results represent significant progress that VisionGate continues to make in the pursuit of innovation in the early detection and treatment of cancer.VisionGate, Inc. is pleased to be attending the AACR Annual Meeting in Chicago April 14-18 where the Company will be presenting late-breaking research:Title: The Malignancy Associated Change Hypothesis Tested Through 3D Cellular Imaging]]>https://www.globenewswire.com/news-release/2018/04/05/1465978/0/en/VisionGate-is-Leveraging-the-Cell-CT-Platform-to-Expand-Cancer-Diagnostics-Services-Biopharmaceutical-Services-and-Cancer-Prevention-Medicines.html?f=22&fvtc=4&fvtv=39817VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines2018-04-05T18:03:42Z<![CDATA[SEATTLE, WA, April 05, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of commercial-capable Cell-CT systems were delivered to VisionGate's clinical laboratory in Phoenix, Arizona earlier this year, setting the stage for the company's advancement."I am pleased to announce that after years of development and refinement, VisionGate's proprietary, breakthrough technology, the Cell-CT platform, is poised to be a key component in the cancer continuum of care ", said Alan C. Nelson, PhD, Chairman and CEO in a statement.]]>https://www.globenewswire.com/news-release/2018/04/04/1460312/0/en/VisionGate-Announces-Two-New-Appointments-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=39817VisionGate Announces Two New Appointments to the Board of Directors2018-04-04T20:21:12Z<![CDATA[Biotech Experienced Directors Further Strengthen the Company Leadership Biotech Experienced Directors Further Strengthen the Company Leadership]]>